TFRC and neoplasm: In contrast, AIE@HFn-scfv leverages dual-receptor targeting (CD71/Claudin18.2) to achieve a tumor-to-background ratio of approximately 2.5-fold higher than single-target probes (Fig. 4, Fig. 5F), enabling submillimeter tumor detection with high specificity.